Zaloguj się

Gotowe bibliografie tematyczne / Platelet activating factor / Artykuły w czasopismach

Artykuły w czasopismach na temat „Platelet activating factor”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Platelet activating factor.

Autor: Grafiati

Data publikacji: 4 czerwca 2021

Data aktualizacji: 31 stycznia 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Platelet activating factor”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

Perry, Seth W., Jason A. Hamilton, Larry W. Tjoelker, Ghassan Dbaibo, Kirk A. Dzenko, Leon G. Epstein, Yusuf Hannun, J. Steven Whittaker, Stephen Dewhurst i Harris A. Gelbard. "Platelet-activating Factor Receptor Activation". Journal of Biological Chemistry 273, nr 28 (10.07.1998): 17660–64. http://dx.doi.org/10.1074/jbc.273.28.17660.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

2

Zhou, W., M. A. Javors i M. S. Olson. "Platelet-activating factor as an intercellular signal in neutrophil-dependent platelet activation." Journal of Immunology 149, nr 5 (1.09.1992): 1763–69. http://dx.doi.org/10.4049/jimmunol.149.5.1763.

Pełny tekst źródła

Streszczenie:

Abstract The role of platelet-activating factor (PAF) in heterotypic cell to cell interactions in a rabbit neutrophil-platelet mixture model was investigated. Platelets were exposed to each of three chemotactic agonists: PAF, leukotriene B4 (LTB4), or FMLP. Only PAF stimulated aggregation, [3H]serotonin secretion, and cytosolic Ca2+ mobilization in platelets alone. However, platelets were stimulated by LTB4 and FMLP in the presence of neutrophils. This neutrophil-dependent platelet activation was blocked by pretreatment of platelets with PAF receptor antagonists, and was prevented by desensitization of platelets to PAF. Furthermore, the time-course of platelet activation showed a positive correlation with PAF production by neutrophils stimulated with either LTB4 or FMLP. The PAF-mediated neutrophil-platelet interaction was dependent on direct cell to cell contact, as demonstrated by experiments in which the majority of newly formed PAF was neutrophil associated (rather than released). Platelet activation did not occur when the neutrophil-platelet mixture was not stirred, minimizing cell to cell contact, or when platelets were challenged with a cell-free supernatant prepared from neutrophils activated with LTB4 or FMLP. Finally, the neutrophil-platelet interaction was abolished by SC-49992, a peptidomimetic of the fibrinogen binding sequence Arg-Gly-Asp-Phe, indicating a Arg-Gly-Asp-specific recognition mechanism. Our results demonstrate that neutrophil-generated PAF plays a crucial role in neutrophil-dependent platelet activation in this model system. This type of intercellular signaling event may be important in certain inflammatory or thrombotic processes.

Style APA, Harvard, Vancouver, ISO itp.

3

KAWASAKI, Tomio, i Jun-ichi KAMBAYASHI. "Platelet-activating Factor". Japanese Journal of Thrombosis and Hemostasis 2, nr 4 (1991): 274–85. http://dx.doi.org/10.2491/jjsth.2.274.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

4

Kingsnorth, A. N. "Platelet-Activating Factor". Scandinavian Journal of Gastroenterology 31, sup219 (styczeń 1996): 28–31. http://dx.doi.org/10.3109/00365529609104996.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

5

McCORMACK, DAVID G., PETER J. BARNES i TIMOTHY W. EVANS. "Platelet-activating factor". Critical Care Medicine 18, nr 12 (grudzień 1990): 1398–402. http://dx.doi.org/10.1097/00003246-199012000-00018.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

6

Martin, John. "PLATELET-ACTIVATING FACTOR". Lancet 332, nr 8626-8627 (grudzień 1988): 1486. http://dx.doi.org/10.1016/s0140-6736(88)90956-7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

7

Humphreys, Randy F. "PLATELET ACTIVATING FACTOR". Southern Medical Journal 83, Supplement (wrzesień 1990): 2S—2. http://dx.doi.org/10.1097/00007611-199009001-00004.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

8

Prescott, S. M., G. A. Zimmerman i T. M. McIntyre. "Platelet-activating factor." Journal of Biological Chemistry 265, nr 29 (październik 1990): 17381–84. http://dx.doi.org/10.1016/s0021-9258(18)38167-5.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

9

Welch, Emily J., Ram P. Naikawadi, Zhenyu Li, Phoebe Lin, Satoshi Ishii, Takao Shimizu, Chinnaswamy Tiruppathi, Xiaoping Du, Papasani V. Subbaiah i Richard D. Ye. "Opposing Effects of Platelet-Activating Factor and Lyso-Platelet-Activating Factor on Neutrophil and Platelet Activation". Molecular Pharmacology 75, nr 1 (17.10.2008): 227–34. http://dx.doi.org/10.1124/mol.108.051003.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

10

Lomazova, K. D., A. M. Polyakova, O. S. Astrina i D. B. Tsukerman. "Platelet activating factor and endotoxin-induced platelet activation". Bulletin of Experimental Biology and Medicine 107, nr 5 (maj 1989): 611–14. http://dx.doi.org/10.1007/bf00841762.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

11

Wimberly, H. C., D. O. Slauson i N. R. Neilsen. "Functional and Biochemical Characterization of Immunologically Derived Equine Platelet-Activating Factor". Veterinary Pathology 22, nr 4 (lipiec 1985): 375–86. http://dx.doi.org/10.1177/030098588502200413.

Pełny tekst źródła

Streszczenie:

Antigen-specific challenge of equine leukocytes induced the non-lytic release of a platelet-activating factor in vitro. The equine platelet-activating factor stimulated the release of serotonin from equine platelets in a dose-responsive manner, independent of the presence of cyclo-oxygenase pathway inhibitors such as indomethacin. Rabbit platelets were also responsive to equine platelet-activating factor. The release of equine platelet-activating factor was a rapid reaction with near maximal secretion taking place in 30 seconds. Addition of equine platelet-activating factor to washed equine platelets stimulated platelet aggregation which could not be inhibited by the presence of aspirin or indomethacin. Platelets preincubated with equine platelet-activating factor became specifically desensitized to equine platelet-activating factor while remaining responsive to other platelet stimuli such as collagen and epinephrine. The following biochemical properties of equine platelet-activating factor are identical to those properties of 1-0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AGEPC): stability upon exposure to air and acid; loss of functional activity after basecatalyzed methanolysis with subsequent acylation that returned all functional activity; and identical relative mobilities on silica gel G plates developed with chloroform:methanol:water (65:35:6, volume/volume). The combined functional and biochemical characteristics of equine platelet-activating factor strongly suggest identity between this naturally occurring, immunologically derived equine factor and AGEPC.

Style APA, Harvard, Vancouver, ISO itp.

12

Johnson, C. D. "Platelet-Activating Factor and Platelet-Activating Factor Antagonists in Acute Pancreatitis". Digestive Surgery 16, nr 2 (1999): 93–101. http://dx.doi.org/10.1159/000018699.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

13

Yasuda, K., M. Takashima, K. Umesaki, S. Urakawa, T. Kamiya, S. Matsuoka, Y. Horikoshi, T. Nakajima i I. Sawaragi. "Platelet activating factor and platelet activating factor acetylhydrolase in uteroplacental circulation". Placenta 15, nr 7 (październik 1994): A94. http://dx.doi.org/10.1016/0143-4004(94)90228-3.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

14

Summers, James B., Steven K. Davidsen i George S. Sheppard. "Platelet Activating Factor Antagonists". Current Pharmaceutical Design 1, nr 2 (wrzesień 1995): 161–90. http://dx.doi.org/10.2174/1381612801666220917215816.

Pełny tekst źródła

Streszczenie:

Platelet Activating Factor (PAF) is a D-glycerol-derived phospholipid which is a potent endogenous mediator of inflammation. PAF is synthesized and released by a variety of cell types and elicits its biological activity by interacting with specific G-protein coupled receptors found on platelets, neutrophils, and other inflammatory cells. The physiological consequences of the interaction of PAF with its receptor includes an increase in vascular permeability, hypotension, bronchoconstriction, and platelet and neutrophil aggregation. These biological effects are consistent with the concept that PAF is involved in a number of inflammatory diseases such as septic shock and asthma. Given the potent pathophysiological effects of PAF, a great deal of effort has been focused on the discovery of agents which block the action of PAF at its receptor. Within the past 10 years, a wide range of structures have been identified as PAF antagonists. These include not only PAF analogs, but also antagonists derived from natural products as well as non-lipid synthetic compounds. Several theories have been proposed to unify these diverse structural classes, but sophisticated molecular models of the receptor have not been widely employed. The discovery of new PAF antagonists has relied heavily on traditional medicinal chemistry approaches. A number of PAF antagonists have advanced to clinical evaluation. While several early compounds demonstrated efficacy in animal models of asthma they have failed to provide benefit for this condition in man. The current generation of potent antagonists are being evaluated as therapies for sepsis, pancreatitis and other disorders.

Style APA, Harvard, Vancouver, ISO itp.

15

Gomez, Federico P., i Robert Rodriguez-Roisin. "Platelet-Activating Factor Antagonists". BioDrugs 14, nr 1 (lipiec 2000): 21–30. http://dx.doi.org/10.2165/00063030-200014010-00003.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

16

Koltai, Matyas, David Hosford, Philippe Guinot, André Esanu i Pierre Braquet. "Platelet Activating Factor (PAF)". Drugs 42, nr 1 (lipiec 1991): 9–29. http://dx.doi.org/10.2165/00003495-199142010-00002.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

17

Koltai, Matyas, i Pierre G. Braquet. "Platelet-activating factor antagonists". Clinical Reviews in Allergy 12, nr 4 (grudzień 1995): 361–80. http://dx.doi.org/10.1007/bf02802300.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

18

Saunders, R. N., i D. A. Handley. "Platelet-Activating Factor Antagonists". Annual Review of Pharmacology and Toxicology 27, nr 1 (kwiecień 1987): 237–55. http://dx.doi.org/10.1146/annurev.pa.27.040187.001321.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

19

Chung, K. F. "Platelet activating factor revisited". Thorax 52, nr 12 (1.12.1997): 1019–20. http://dx.doi.org/10.1136/thx.52.12.1019.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

20

Roudebush, William. "Seminal Platelet-Activating Factor". Seminars in Thrombosis and Hemostasis 33, nr 1 (luty 2007): 069–74. http://dx.doi.org/10.1055/s-2006-958464.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

21

Lee, Tae-Yoon. "Platelet Activating Factor-Acetylhydrolase". Yeungnam University Journal of Medicine 24, nr 2 Suppl (31.12.2007): S142–151. http://dx.doi.org/10.12701/yujm.2007.24.2s.s142.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

22

Honda, Z. i., S. Ishii i T. Shimizu. "Platelet-Activating Factor Receptor". Journal of Biochemistry 131, nr 6 (1.06.2002): 773–79. http://dx.doi.org/10.1093/oxfordjournals.jbchem.a003164.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Stafforini, Diana M., Thomas M. McIntyre, Guy A. Zimmerman i Stephen M. Prescott. "Platelet-activating Factor Acetylhydrolases". Journal of Biological Chemistry 272, nr 29 (18.07.1997): 17895–98. http://dx.doi.org/10.1074/jbc.272.29.17895.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

24

Arai, Hiroyuki. "Platelet-activating factor acetylhydrolase". Prostaglandins & Other Lipid Mediators 68-69 (sierpień 2002): 83–94. http://dx.doi.org/10.1016/s0090-6980(02)00023-0.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

25

Ishii, Satoshi, Takahide Nagase i Takao Shimizu. "Platelet-activating factor receptor". Prostaglandins & Other Lipid Mediators 68-69 (sierpień 2002): 599–609. http://dx.doi.org/10.1016/s0090-6980(02)00058-8.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Izumi, Takashi, Tomoko Takano, Haruhiko Bito, Motonao Nakamura, Hiroyuki Mutoh, Zen-ichiro Honda i Takao Shinizu. "Platelet-activating factor receptor". Journal of Lipid Mediators and Cell Signalling 12, nr 2-3 (październik 1995): 429–42. http://dx.doi.org/10.1016/0929-7855(95)00028-o.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

27

Karpouza, Angeliki P., i Catherine Vakirtzi-Lemonias. "The platelet-activating factor acetylhydrolase of mouse platelets". Biochimica et Biophysica Acta (BBA) - Biomembranes 1323, nr 1 (styczeń 1997): 12–22. http://dx.doi.org/10.1016/s0005-2736(96)00178-2.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

28

Chesney, Carolyn M., D. David Pifer i Kim M. Huch. "Desensitization of human platelets by platelet activating factor". Biochemical and Biophysical Research Communications 127, nr 1 (luty 1985): 24–30. http://dx.doi.org/10.1016/s0006-291x(85)80120-0.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

29

VALONE, F. "Synthesis of platelet-activating factor by human monocytes stimulated by platelet-activating factor". Journal of Allergy and Clinical Immunology 87, nr 3 (marzec 1991): 715–20. http://dx.doi.org/10.1016/0091-6749(91)90394-4.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

30

Bevers, Edouard, Theo Lindhout i Johan Heemskerk. "Platelet Activation and Blood Coagulation". Thrombosis and Haemostasis 88, nr 08 (2002): 186–93. http://dx.doi.org/10.1055/s-0037-1613209.

Pełny tekst źródła

Streszczenie:

SummaryPlatelet activation and blood coagulation are complementary, mutually dependent processes in haemostasis and thrombosis. Platelets interact with several coagulation factors, while the coagulation product thrombin is a potent platelet-activating agonist. Activated platelets come in a procoagulant state after a prolonged elevation in cytosolic [Ca2+]i. Such platelets, e. g. when adhering to collagen via glycoprotein VI, expose phosphatidylserine (PS) at their outer surface and produce (PS-exposing) membrane blebs and microvesicles. Inhibition of aminophospholipid translocase and activation of phospholipid scramblase mediate the exposure of PS, whereas calpain-mediated protein cleavage leads to membrane blebbing and vesiculation. Surface-exposed PS strongly propagates the coagulation process by facilitating the assembly and activation of tenase and prothrombinase complexes. Factor IXa and platelet-bound factor Va support these activities. In addition, platelets can support the initiation phase of coagulation by providing binding sites for prothrombin and factor XI. They thereby take over the initiating role of tissue factor and factor VIIa in coagulation activation.

Style APA, Harvard, Vancouver, ISO itp.

31

SATOH, Kei, Shigeru TAKAMATSU, Yoko KAWAMURA, Seitoku MIZUNO, Bun-ichiro SHOJI i Mutsu TAKAMATSU. "Plasma Platelet-Activating Factor (PAF) Acetylhydrolase and Lipoproteins in Patients with Cerebral Thrombosis". Journal of Japan Atherosclerosis Society 15, nr 3 (1987): 727–33. http://dx.doi.org/10.5551/jat1973.15.3_727.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

32

Schulam, P. G., A. Kuruvilla, G. Putcha, L. Mangus, J. Franklin-Johnson i W. T. Shearer. "Platelet-activating factor induces phospholipid turnover, calcium flux, arachidonic acid liberation, eicosanoid generation, and oncogene expression in a human B cell line." Journal of Immunology 146, nr 5 (1.03.1991): 1642–48. http://dx.doi.org/10.4049/jimmunol.146.5.1642.

Pełny tekst źródła

Streszczenie:

Abstract Platelet-activating factor is a potent mediator of the inflammatory response. Studies of the actions of platelet-activating factor have centered mainly around neutrophils, monocytes, and platelets. In this report we begin to uncover the influence of platelet-activating factor on B lymphocytes. Employing the EBV-transformed human B cell line SKW6.4, we demonstrate that platelet-activating factor significantly alters membrane phospholipid metabolism indicated by the incorporation of 32P into phosphatidylcholine, phosphatidylinositol, and phosphatidic acid but not significantly into phosphatidylethanolamine at concentrations ranging from 10(-9) to 10(-6) M. The inactive precursor, lyso-platelet-activating factor, at a concentration as high as 10(-7) M had no effect on any of the membrane phospholipids. We also show that platelet-activating factor from 10(-12) to 10(-6) M induced rapid and significant elevation in intracellular calcium levels, whereas lyso-platelet-activating factor was again ineffective. We further demonstrate the impact of platelet-activating factor binding to B cells by measuring platelet-activating factor induced arachidonic acid release and 5-hydroxyeicosatetraenoic acid production. Moreover, platelet-activating factor was capable of inducing transcription of the nuclear proto-oncogenes c-fos and c-jun. Finally we explored the possible role of 5-hydroxyeicosatetraenoic acid as a regulator of arachidonic acid liberation demonstrating that endogenous 5-lipoxygenase activity modulates platelet-activating factor induced arachidonic acid release perhaps acting at the level of phospholipase A2. In summary, platelet-activating factor is shown here to have a direct and profound effect on a pure B cell line.

Style APA, Harvard, Vancouver, ISO itp.

33

Duronio, Vincent, Anne Reany, Sandra Wong, Chantal Bigras i Hassan Salari. "Characterization of platelet-activating factor receptors in porcine platelets". Canadian Journal of Physiology and Pharmacology 68, nr 12 (1.12.1990): 1514–19. http://dx.doi.org/10.1139/y90-230.

Pełny tekst źródła

Streszczenie:

Despite a large number of studies describing the properties and effects of platelet-activating factor (PAF), little is known about its receptor structure. The characterization of the PAF receptor from additional cell types and species is important for the design of strategies to purify and characterize the receptor molecule. Porcine platelets were shown to bind PAF with characteristics similar to several other species, based on receptor number, affinity, and the activity of PAF antagonists. We found that the affinity for binding was higher in porcine than in rabbit platelets (Kd = 0.68 ± 0.13 nM for rabbit and 0.29 ± 0.10 nM for porcine). Porcine platelets have approximately 281 ± 158 receptors per cell compared with 689 ± 229 receptors in rabbit platelets. Rabbit platelets respond to concentrations of PAF that are approximately 105-fold lower than those required for aggregation of porcine platelets, but this difference is probably not due to the differences in receptor number alone. When binding was compared between purified membranes from these two cell types, porcine platelets had 20-fold fewer receptors per milligram of membrane protein, but this difference may have been due to an artifact of the membrane preparation procedure. Binding of PAF was severely hindered at cold temperatures. It was undetectable in whole cells on ice and greatly reduced with purified membranes. This study is the first to characterize PAF receptors in porcine platelets, which represent a potentially useful source of receptor for further biochemical characterization.Key words: platelet activating factor, receptor, porcine, platelet, membrane.

Style APA, Harvard, Vancouver, ISO itp.

34

Potron, G., E. Petitfrere i P. Nguyen. "Platelet activating factor and ischemia". Clinical Hemorheology and Microcirculation 13, nr 2 (1993): 155–76. http://dx.doi.org/10.3233/ch-1993-13202.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

35

O'Neill, C. "Embryo-derived platelet activating factor". Reproduction, Fertility and Development 4, nr 3 (1992): 283. http://dx.doi.org/10.1071/rd9920283.

Pełny tekst źródła

Streszczenie:

Platelet-activating factor (PAF) is secreted by the preimplantation embryo of a number of species. The role of this secretion is yet to be fully elucidated. Evidence to date indicates that it has an important function as an autocrine stimulant of embryonic metabolism, growth and viability. Production of PAF by embryos appears to be severely compromised in vitro. This may be a major cause of reduced embryo viability following embryo culture and it may also help to explain the controversy in the literature regarding the production of PAF by embryos. PAF also alters several aspects of maternal physiology during early pregnancy including endometrial prostaglandin secretion. The significance of these changes remains to be defined.

Style APA, Harvard, Vancouver, ISO itp.

36

Greaves, M. W., i M. R. Judge. "Platelet activating factor in psoriasis". British Journal of Dermatology 136, nr 3 (marzec 1997): 467. http://dx.doi.org/10.1111/j.1365-2133.1997.tb14968.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

37

O'NEILL, CHRISTOPHER, MELANIE COLLIER i DOUGLAS M. SAUNDERS. "Embryo-Derived Platelet-Activating Factor." Annals of the New York Academy of Sciences 541, nr 1 In Vitro Fert (październik 1988): 398–406. http://dx.doi.org/10.1111/j.1749-6632.1988.tb22276.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

38

Tsuda, Makoto, Hidetoshi Tozaki-Saitoh i Kazuhide Inoue. "Platelet-Activating Factor and Pain". Biological & Pharmaceutical Bulletin 34, nr 8 (2011): 1159–62. http://dx.doi.org/10.1248/bpb.34.1159.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

39

Pałgan, Krzysztof, i Zbigniew Bartuzi. "Platelet activating factor in allergies". International Journal of Immunopathology and Pharmacology 28, nr 4 (20.10.2015): 584–89. http://dx.doi.org/10.1177/0394632015600598.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Minhas, B. S., B. A. Ripps, Y. P. Zhu, H. N. Kim, T. H. Burwinkel i N. Gleicher. "Platelet Activating Factor and Conception". American Journal of Reproductive Immunology 35, nr 3 (marzec 1996): 267–71. http://dx.doi.org/10.1111/j.1600-0897.1996.tb00043.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

41

Stafforini, Diana M., Stephen M. Prescott, Guy A. Zimmerman i Thomas M. McIntyre. "Mammalian platelet-activating factor acetylhydrolases". Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1301, nr 3 (czerwiec 1996): 161–73. http://dx.doi.org/10.1016/0005-2760(96)00040-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

42

Barnes, Peter J. "Platelet-activating factor and asthma". Journal of Allergy and Clinical Immunology 81, nr 1 (styczeń 1988): 152–60. http://dx.doi.org/10.1016/0091-6749(88)90234-5.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

43

Peters, Ulrike, Wassja Bankova i Peter Welzel. "Platelet activating factor synthetic studies". Tetrahedron 43, nr 16 (styczeń 1987): 3803–16. http://dx.doi.org/10.1016/s0040-4020(01)86866-6.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

44

BARNES, PETER J. "Platelet Activating Factor and Asthma". Annals of the New York Academy of Sciences 629, nr 1 Advances in t (lipiec 1991): 193–204. http://dx.doi.org/10.1111/j.1749-6632.1991.tb37976.x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

45

Morley, J. "Platelet activating factor and asthma". Agents and Actions 19, nr 1-2 (październik 1986): 100–108. http://dx.doi.org/10.1007/bf01977264.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Karasawa, Ken, Noriko Satoh, Toshio Hongo, Yasuhito Nakagawa, Morio Setaka i Shoshichi Nojima. "Radioimmunoassay for platelet-activating factor". Lipids 26, nr 12 (grudzień 1991): 1126–29. http://dx.doi.org/10.1007/bf02536515.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

47

Furukawa, Masayuki, Edward L. Lee i John M. Johnston. "Platelet-Activating Factor–Induced Ischemic Bowel Necrosis: The Effect of Platelet-Activating Factor Acetylhydrolase". Pediatric Research 34, nr 2 (sierpień 1993): 237–41. http://dx.doi.org/10.1203/00006450-199308000-00027.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

48

Masugi, Fuminori, Toshio Ogihara, Shuichi Saeki, Katsuhiko Sakaguchi, Yuichi Kumahara, Kiyoshi Satouchi, Makoto Oda, Kunihiko Saito i Koh Tokunaga. "Endogenous platelet-activating factor and anti-platelet-activating factor in patients with renovascular hypertension". Life Sciences 42, nr 4 (styczeń 1988): 455–60. http://dx.doi.org/10.1016/0024-3205(88)90084-7.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

49

Travers, Jeffrey B., Qian Li, Howard Sprecher i Richard H. Fertel. "Binding of carbamyl-platelet-activating factor to the raji lymphoblast platelet-activating factor receptor". International Journal of Immunopharmacology 14, nr 4 (maj 1992): 515–23. http://dx.doi.org/10.1016/0192-0561(92)90112-x.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

50

Mabuchi-Itoh, Kiyoko, Takayuki Sugiura, Neng-neng Cheng i Keizo Waku. "Aspirin induces non-enzymatic formation of platelet-activating factor from lyso platelet-activating factor". FEBS Letters 332, nr 3 (18.10.1993): 233–36. http://dx.doi.org/10.1016/0014-5793(93)80639-c.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!